Literature DB >> 8118454

[Socioeconomic costs of osteoarthritis in France].

E Levy1, A Ferme, D Perocheau, I Bono.   

Abstract

The purpose of this study was to quantify the social and financial burden imposed by osteoarthritis in France. Six million new diagnoses of osteoarthritis are reported each year in France. The number of physician visits for osteoarthritis totals 8.7 million per year, for a total cost of 950 million French francs (FF). The cost of drugs prescribed to treat osteoarthritis is 965 million FF. Total annual cost of laboratory tests, roentgenograms, and rehabilitation therapy is 330 million French francs per year. The annual number of hospital admissions for osteoarthritis is 93,000. Duration of the hospital stay ranges from 11 to 16 days according the site involved. Hospital costs (in public and private institutions) total 1.7 billion French francs per year. Total direct costs related to osteoarthritis are 4 billion French francs per year. Indirect costs are the costs related to days of work lost. Sick leave benefits total 556 million FF and the production costs for the national economy are estimated at 1.6 billion French francs per year. Direct costs (4 billion FF) and indirect costs (at least 600 million FF) related to osteoarthritis represent an enormous burden for the French economy and national health care system. Novel treatments capable of substantially decreasing these costs would be of great value.

Entities:  

Mesh:

Year:  1993        PMID: 8118454

Source DB:  PubMed          Journal:  Rev Rhum Ed Fr        ISSN: 1169-8330


  10 in total

Review 1.  Prolotherapy in primary care practice.

Authors:  David Rabago; Andrew Slattengren; Aleksandra Zgierska
Journal:  Prim Care       Date:  2010-03       Impact factor: 2.907

Review 2.  Economic evaluation of the management of pain in osteoarthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.

Authors:  Manouche Tavakoli
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Prolotherapy for Osteoarthritis and Tendinopathy: a Descriptive Review.

Authors:  David Rabago; Bobby Nourani
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

Review 5.  The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review.

Authors:  E Hunsche; J V Chancellor; N Bruce
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Osteoarthritis: can anti-cytokine therapy play a role in treatment?

Authors:  Ana Luisa G Calich; Diogo S Domiciano; Ricardo Fuller
Journal:  Clin Rheumatol       Date:  2010-01-27       Impact factor: 2.980

7.  Prosthesis infections after orthopedic joint replacement: the possible role of bacterial biofilms.

Authors:  Zhijun Song; Lotte Borgwardt; Niels Høiby; Hong Wu; Torben Sandberg Sørensen; Arne Borgwardt
Journal:  Orthop Rev (Pavia)       Date:  2013-06-14

8.  The Global Economic Cost of Osteoarthritis: How the UK Compares.

Authors:  A Chen; C Gupte; K Akhtar; P Smith; J Cobb
Journal:  Arthritis       Date:  2012-10-02

9.  How much do rheumatologists and orthopaedists doctors' modalities impact the cost of arthritis in Cyprus?

Authors:  Despena Andrioti; Kypros Kyprianou; George Charalambous
Journal:  BMC Musculoskelet Disord       Date:  2015-08-14       Impact factor: 2.362

10.  Usual care including home exercise with versus without spa therapy for chronic low back pain: protocol for the LOMBATHERM' study, a multicentric randomised controlled trial.

Authors:  Romain Forestier; Carey Suehs; Alain Françon; Marc Marty; Stéphane Genevay; Jérémie Sellam; Claire Chauveton; Fatma Begüm Erol Forestier; Nicolas Molinari
Journal:  Trials       Date:  2020-05-11       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.